BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 17199440)

  • 21. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study.
    Elisei R; Ugolini C; Viola D; Lupi C; Biagini A; Giannini R; Romei C; Miccoli P; Pinchera A; Basolo F
    J Clin Endocrinol Metab; 2008 Oct; 93(10):3943-9. PubMed ID: 18682506
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes.
    Vasko V; Hu S; Wu G; Xing JC; Larin A; Savchenko V; Trink B; Xing M
    J Clin Endocrinol Metab; 2005 Sep; 90(9):5265-9. PubMed ID: 15998781
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection of RET/PTC, TRK and BRAF mutations in preoperative diagnosis of thyroid nodules with indeterminate cytological findings.
    Sapio MR; Posca D; Raggioli A; Guerra A; Marotta V; Deandrea M; Motta M; Limone PP; Troncone G; Caleo A; Rossi G; Fenzi G; Vitale M
    Clin Endocrinol (Oxf); 2007 May; 66(5):678-83. PubMed ID: 17381488
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Different structural components of conventional papillary thyroid carcinoma display mostly identical BRAF status.
    Abrosimov A; Saenko V; Rogounovitch T; Namba H; Lushnikov E; Mitsutake N; Yamashita S
    Int J Cancer; 2007 Jan; 120(1):196-200. PubMed ID: 17044028
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Papillary thyroid carcinoma with prominent hobnail features: a new aggressive variant of moderately differentiated papillary carcinoma. A clinicopathologic, immunohistochemical, and molecular study of eight cases.
    Asioli S; Erickson LA; Sebo TJ; Zhang J; Jin L; Thompson GB; Lloyd RV
    Am J Surg Pathol; 2010 Jan; 34(1):44-52. PubMed ID: 19956062
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BRAF(V600E) mutation and the biology of papillary thyroid cancer.
    Frasca F; Nucera C; Pellegriti G; Gangemi P; Attard M; Stella M; Loda M; Vella V; Giordano C; Trimarchi F; Mazzon E; Belfiore A; Vigneri R
    Endocr Relat Cancer; 2008 Mar; 15(1):191-205. PubMed ID: 18310287
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The heterogeneous distribution of BRAF mutation supports the independent clonal origin of distinct tumor foci in multifocal papillary thyroid carcinoma.
    Giannini R; Ugolini C; Lupi C; Proietti A; Elisei R; Salvatore G; Berti P; Materazzi G; Miccoli P; Santoro M; Basolo F
    J Clin Endocrinol Metab; 2007 Sep; 92(9):3511-6. PubMed ID: 17535994
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
    Costa AM; Herrero A; Fresno MF; Heymann J; Alvarez JA; Cameselle-Teijeiro J; García-Rostán G
    Clin Endocrinol (Oxf); 2008 Apr; 68(4):618-34. PubMed ID: 18070147
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BRAF mutation analysis in fine needle aspiration (FNA) cytology of the thyroid.
    Jin L; Sebo TJ; Nakamura N; Qian X; Oliveira A; Majerus JA; Johnson MR; Lloyd RV
    Diagn Mol Pathol; 2006 Sep; 15(3):136-43. PubMed ID: 16932068
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Use of BRAF V600E mutation in the differential diagnosis of follicular and papillary tumors of the thyroid and for the optimization of thearpy].
    Semënov DIu; Boriskova ME; Zaraĭskiĭ MI; Saburova IIu; Pankova PA; Farafonova UV; Bykov MA
    Vopr Onkol; 2012; 58(5):649-52. PubMed ID: 23600282
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [BRAF mutation and papillary thyroid cancer].
    Yi W; Zhong D; Zou Q
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2012 Apr; 37(4):370-3. PubMed ID: 22561568
    [TBL] [Abstract][Full Text] [Related]  

  • 32. RET rearrangements and BRAF mutation in undifferentiated thyroid carcinomas having papillary carcinoma components.
    Mochizuki K; Kondo T; Nakazawa T; Iwashina M; Kawasaki T; Nakamura N; Yamane T; Murata S; Ito K; Kameyama K; Kobayashi M; Katoh R
    Histopathology; 2010 Sep; 57(3):444-50. PubMed ID: 20840674
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature.
    Fugazzola L; Puxeddu E; Avenia N; Romei C; Cirello V; Cavaliere A; Faviana P; Mannavola D; Moretti S; Rossi S; Sculli M; Bottici V; Beck-Peccoz P; Pacini F; Pinchera A; Santeusanio F; Elisei R
    Endocr Relat Cancer; 2006 Jun; 13(2):455-64. PubMed ID: 16728573
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of molecular markers and tumor histological type in central lymph node metastasis of papillary thyroid carcinoma.
    Paulson L; Shindo M; Schuff K; Corless C
    Arch Otolaryngol Head Neck Surg; 2012 Jan; 138(1):44-9. PubMed ID: 22249628
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Medullary and papillary carcinoma of the thyroid gland occurring as a collision tumour: report of three cases with molecular analysis and review of the literature.
    Rossi S; Fugazzola L; De Pasquale L; Braidotti P; Cirello V; Beck-Peccoz P; Bosari S; Bastagli A
    Endocr Relat Cancer; 2005 Jun; 12(2):281-9. PubMed ID: 15947103
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of iodine metabolism genes in human thyroid tissues: evidence for age and BRAFV600E mutation dependency.
    Espadinha C; Santos JR; Sobrinho LG; Bugalho MJ
    Clin Endocrinol (Oxf); 2009 Apr; 70(4):629-35. PubMed ID: 18710471
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
    Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
    Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Expression of BRAF V600E mutation in different thyroid lesions].
    Wang W; Li XH; Zhang YH; Li J; Chen J; Zhao P; Li QY; Xiang JJ; Li X; Xu RJ
    Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):354-7. PubMed ID: 21875464
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of the sodium iodide symporter and thyroglobulin genes are reduced in papillary thyroid cancer.
    Ringel MD; Anderson J; Souza SL; Burch HB; Tambascia M; Shriver CD; Tuttle RM
    Mod Pathol; 2001 Apr; 14(4):289-96. PubMed ID: 11301345
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical role of BRAF V600E mutation testing in thyroid nodules].
    Wan H; Zhang B; Wang Y; Xiao T; Guo H; Liu W; Yan D; Xu Z; Tang P
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2014 Jun; 49(6):468-72. PubMed ID: 25241863
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.